Advertisement
Advertisement
CLLS
Cellectis S.A. - ADR
1.11
USDSponsored
-0.01
-0.89%
Nov 10, 15:13 UTC -5
Closed
After-Market
1.11
0.00
-0.09%
Cellectis S.A. - ADR (CLLS) Earnings
CLLS Earnings Reports
Positive Surprise Ratio
CLLS beat 17 of 24 last estimates.
71%
Next Report
Date of Next Report
Mar 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
$13.69M
/-$0.18
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
+12.16%
/-30.77%
Cellectis S.A. - ADR earnings per share and revenue
On Nov 09, 2026, CLLS reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.17 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 16.08 million, with a --% difference.
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.18 USD, with revenue projected to reach 13.69 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Cellectis S.A. - ADR's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Cellectis S.A. - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Cellectis S.A. - ADR's Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Cellectis S.A. - ADR expected to report next?
The next earning report is scheduled for Mar 10, 2027.
What are the forecasts for Cellectis S.A. - ADR's next earnings report?
Based on --
analysts, Cellectis S.A. - ADR is expected to report EPS of -$0.18 and revenue of $13.69M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.